Browsed by
Tag: phase

Oral Apremilast Significantly Improved Nail and Scalp Psoriasis and Health-Related Quality-of-Life Measures in Phase III ESTEEM 1 Study ?>

Oral Apremilast Significantly Improved Nail and Scalp Psoriasis and Health-Related Quality-of-Life Measures in Phase III ESTEEM 1 Study

Oral OTEZLA(R) (apremilast) Data Presented at EADV Show Improved Measures of Health-Related Quality of Life and Work Productivity in Patients with Moderate to Severe Plaque Psoriasis. Apremilast treatment resulted in improved health-related quality of life during 16 weeks of therapy in ESTEEM 2. Oral Apremilast Significantly Improved Nail and Scalp Psoriasis and Health-Related Quality-of-Life Measures in Phase III ESTEEM 1 Study Patients in ESTEEM 1 trial with nail and scalp psoriasis showed significant improvement with apremilast at 16 weeks; improvements…

Read More Read More

Cellceutix Commences Phase 2 Trial of Prurisol as New Treatment for Psoriasis ?>

Cellceutix Commences Phase 2 Trial of Prurisol as New Treatment for Psoriasis

Top-Line Data on Prurisol Expected in 2nd Quarter. BEVERLY, MA–(Marketwired – January 25, 2016) – Cellceutix Corporation (OTC: CTIX) (the Company ), a clinical stage biopharmaceutical company developing innovative therapies with oncology, dermatology, anti-inflammatory and antibiotic applications, is pleased to announce that approximately 75 percent of the subjects enrolled in the Company’s Phase 2 clinical trial of Prurisol for the treatment of chronic plaque psoriasis have completed dosing, defined as 84 days of daily treatments of Prurisol or placebo. Cellceutix…

Read More Read More

The results of the phase II trials support IL-23 as an essential target in psoriasis treatment ?>

The results of the phase II trials support IL-23 as an essential target in psoriasis treatment

Anti-IL-23 Phase II Data for Psoriasis: A Review. The results of the phase II trials support IL-23 as an essential target in psoriasis treatment. The results of the phase II trials support the theory that the IL-17 pathway is an essential target in psoriasis treatment. Discovery of the cytokine IL-23, which shares a common p40 subunit with IL-12, prompted efforts to clarify the relative contribution of these two cytokines in immune regulation. Briakinumab’s phase 3 results are from clinical trials…

Read More Read More

Ustekinumab is approved for treating moderate to severe psoriasis, as established in large phase three trials ?>

Ustekinumab is approved for treating moderate to severe psoriasis, as established in large phase three trials

In large clinical trials, ustekinumab has proven effective for treating moderate to severe plaque psoriasis. Phase 2 trial was carried out in 320 patients with moderate-to-severe plaque psoriasis. Ustekinumab in the treatment of psoriatic arthritis: latest findings and clinical potential. In September 2009, the US Food and Drug Administration (FDA) approved its use for adult patients with moderate-to-severe plaque psoriasis. Before reviewing the three large trials of UST in PsA, a brief review of UST in psoriasis will be helpful…

Read More Read More

The phase II psoriasis trial of 176 patients demonstrated positive efficacy results with no unexpected safety issues ?>

The phase II psoriasis trial of 176 patients demonstrated positive efficacy results with no unexpected safety issues

The phase II psoriasis trial of 176 patients demonstrated positive efficacy results with no unexpected safety issues. Patients were randomized to CZP 200 mg queow, CZP 400 mg qmonth, or placebo. In 2005, there was a large phase II psoriasis trial of 176 patients with 10 percent BSA and PASI 12. There were no unexpected safety issues. The phase II studies, which were completed some time ago, demonstrated positive efficacy results along with a good safety profile. The phase II…

Read More Read More

Galectin Therapeutics Begins Phase 2a Psoriasis Study With GR-MD-02 ?>

Galectin Therapeutics Begins Phase 2a Psoriasis Study With GR-MD-02

We know from the scientific literature that galectin-3 is at higher levels in the skin of psoriasis patients, and that GR-MD-02 inhibits galectin-3. A second Phase 1B study is planned to begin in 1Q-2016 2016. A Psoriasis phase 2a trial in moderate to severe plaque psoriasis patients began in January 2016. The Phase 1 trial was completed and demonstrated that GR-MD-02 up to 8 mg/Kg, i. Galectin Therapeutics Begins Phase 2a Psoriasis Study With GR-MD-02. Galectin Therapeutics, Inc. (Nasdaq: GALT)…

Read More Read More

Cellceutix Nears Completion of Phase 2 Trial of New Oral Treatment for Psoriasis ?>

Cellceutix Nears Completion of Phase 2 Trial of New Oral Treatment for Psoriasis

This dose-ranging trial is near completion. We have collected enough data for planning Phase 2 trials. This data is being used to design the Kevetrin dosing regimen for the planned studies in patients with advanced ovarian carcinoma. The four-arm multi-center Phase 2 trial, three arms with different dosing regimens of Prurisol and one arm placebo, is designed to assess the efficacy and safety of Prurisol given orally compared to placebo in a randomized, double-blind setting in patients with mild to…

Read More Read More

Background/Purpose Secukinumab has demonstrated significant and rapid efficacy in the treatment of psoriasis in two phase 3 studies ?>

Background/Purpose Secukinumab has demonstrated significant and rapid efficacy in the treatment of psoriasis in two phase 3 studies

Alice B. Gottlieb1, Philip J. Mease2, Iain B. McInnes3, Bruce Kirkham4, Arthur Kavanaugh5, Proton Rahman6, Peter Nash7, Luminita Pricop8, Jiacheng Yuan9, Hanno Richards10 and Shephard Mpofu11, 1Tufts Medical Center, Boston, MA, 2Swedish Medical Center and University of Washington, Seattle, WA, 3University of Glasgow, Glasgow, United Kingdom, 4Guy’s and St Thomas’ NHS Foundation Trust, London, United Kingdom, 5UCSD School of Medicine, La Jolla, CA, 6Faculty of Medicine, Memorial University of Newfoundland, St. Iain B. McInnes1,2, Philip J. Mease3, Bruce Kirkham4, Arthur…

Read More Read More

Niosomal methotrexate gel in the treatment of localized psoriasis: Phase I and phase II studies ?>

Niosomal methotrexate gel in the treatment of localized psoriasis: Phase I and phase II studies

Key words: Novel carriers, topical, antipsoriatic drugs, psoriasis, skin. 2 Pustular 3 Guttate 4 Flexural 5 Erythrodermic factor (TNF)-, and interferon (IFN)-. Abstract In the formulation of topical dosage forms, more attention has been devoted to new structures, which can ensure either adequate localization of drug within the skin to enhance the local effect or can increase the penetration through the stratum corneum. On MTX, only few studies are available on topical formulation. If a subject develops a level 2…

Read More Read More

Cellceutix’s anti-psoriasis drug Prurisol is in a Phase 2 trial ?>

Cellceutix’s anti-psoriasis drug Prurisol is in a Phase 2 trial

Cellceutix Concludes Last Patient Visit in Phase 2 FDA Trial of Oral Dosed Prurisol in Patients With Mild-to-Moderate Chronic Plaque Psoriasis. Cellceutix’s anti-psoriasis drug Prurisol is in a Phase 2 trial. Cellceutix Completes Dosing in Phase 2 Trial of Prurisol for Chronic Psoriasis, Top-Line Data Anticipated in May. Cellceutix’s anti-psoriasis drug Prurisol is in a Phase 2 trial. Cellceutix s anti-cancer drug Kevetrin is currently in a Phase 1 clinical trial at Harvard Cancer Centers Dana Farber Cancer Institute and…

Read More Read More